9,084 Insulet Corporation $PODD Shares Sold by Redmond Asset Management LLC

Redmond Asset Management LLC reduced its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 43.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,891 shares of the medical instruments supplier’s stock after selling 9,084 shares during the period. Redmond Asset Management LLC’s holdings in Insulet were worth $1,551,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. State of Wyoming boosted its position in Insulet by 34.6% in the 1st quarter. State of Wyoming now owns 284 shares of the medical instruments supplier’s stock valued at $60,000 after buying an additional 73 shares during the period. Optas LLC increased its position in shares of Insulet by 8.8% during the first quarter. Optas LLC now owns 1,059 shares of the medical instruments supplier’s stock worth $222,000 after acquiring an additional 86 shares during the period. American Trust raised its stake in shares of Insulet by 8.6% in the first quarter. American Trust now owns 1,180 shares of the medical instruments supplier’s stock valued at $248,000 after acquiring an additional 93 shares in the last quarter. Basecamp Wealth Advisors LLC raised its stake in shares of Insulet by 48.3% in the first quarter. Basecamp Wealth Advisors LLC now owns 313 shares of the medical instruments supplier’s stock valued at $66,000 after acquiring an additional 102 shares in the last quarter. Finally, Elevation Wealth Partners LLC raised its stake in shares of Insulet by 115.6% in the third quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 104 shares in the last quarter.

Wall Street Analyst Weigh In

Several research firms have commented on PODD. Royal Bank Of Canada lowered their price target on shares of Insulet from $245.00 to $160.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Citigroup boosted their target price on shares of Insulet from $165.00 to $172.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 8th. Wells Fargo & Company downgraded shares of Insulet from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $255.00 to $144.00 in a research note on Wednesday, August 5th. Benchmark cut their price target on Insulet from $250.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Finally, Wall Street Zen downgraded Insulet from a “buy” rating to a “hold” rating in a report on Saturday, October 24th. Thirteen investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $186.68.

Insulet Stock Performance

Shares of PODD opened at $148.93 on Thursday. The company’s 50 day simple moving average is $140.84 and its 200-day simple moving average is $181.20. The firm has a market cap of $10.33 billion, a PE ratio of 27.84, a price-to-earnings-growth ratio of 1.17 and a beta of 1.11. Insulet Corporation has a 12-month low of $126.40 and a 12-month high of $354.88. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The firm had revenue of $801.70 million during the quarter, compared to analysts’ expectations of $787.39 million. During the same quarter in the prior year, the business earned $1.17 EPS. Insulet’s quarterly revenue was up 23.5% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, equities analysts predict that Insulet Corporation will post 6.51 EPS for the current year.

Insulet Profile

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.